CAR T-cell therapy comes of age: Introductory editorial for the special issue
- 15 October 2024
- journal article
- editorial
- Published by Elsevier in Seminars in Hematology
- Vol. 61 (5) , 271-272
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?Seminars in Hematology, 2024
- CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic MalignanciesSeminars in Hematology, 2024
- The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALLSeminars in Hematology, 2024
- The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19Seminars in Hematology, 2024
- Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapySeminars in Hematology, 2024
- Fast and Furious: changing gears on the road to cure with chimeric antigen receptor T cells in multiple myelomaSeminars in Hematology, 2024
- Tuning CAR T-cell therapies for efficacy and reduced toxicitySeminars in Hematology, 2024
- License for a CAR T: Examining patient eligibilitySeminars in Hematology, 2024
- The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature ReviewCancers, 2023
- Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaNew England Journal of Medicine, 2023